Unprecedented PRESERVE IVC Filter Study Unites Surgeons, Interventionalists, Manufacturers, And The FDA
Executive Summary
An unprecedented clinical trial called PRESERVE is bringing together the Society of Interventional Radiology, the Society for Vascular Surgery, major manufacturers of inferior vena cava filters, and the FDA to answer questions about how the filter might best fit into modern medicine.
You may also be interested in...
More Bad News About IVC Filters From National Database Study
A nationwide observational study found that adjunctive inferior vena cava filter placement in patients undergoing catheter-directed thrombolysis does not reduce in-hospital mortality, but increases inpatient charges and length of stay. One-third of all patients undergoing catheter-directed thrombolysis receive IVC filters.
Novate: Re-Newing The IVC Filter Market
Serial medtech entrepreneurs Chas Taylor and Paul Gilson founded Novate Medical Ltd. to develop a bioconvertible inferior vena cava filter – it protects patients from pulmonary embolisms during a critical interval, then integrates into the vessel wall. There is no need to retrieve it, a benefit that goes far beyond the economics of avoiding a second procedure.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”